Dr. Joe Tucker, CEO of Enveric Biosciences [The Green Rush]
Thursday, February 29, 2024 1 min read
Key Takeaway: Dr. Joseph Tucker, CEO of Enveric Biosciences, discusses the company's advancements in neuroplastogen therapeutics, particularly highlighting EB-003 as the lead candidate in the EVM 301 series. The conversation also provides insights for retail investors interested in drug discovery within the neuropsychiatric space.
Price reaction · baseline $149.58 (2024-02-28 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
+74.5%
day 1
+99.8%
day 3
+69.7%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is focused on innovative neuroplastogen therapeutics.
EB-003 has been selected as the lead candidate, indicating progress.
The discussion includes valuable insights for retail investors.
Full Press Release Details
This week Anne Donohoe and Nick Opich talk to Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for the treatment of neuropsychiatric disorders. Dr. Tucker joins us to discuss the latest news and milestones for the company, including the selection of EB-003 as its lead candidate in its EVM 301 series, plus advice to the retail investor audience on continuing drug discovery investments in the psych space.
Frequently Asked Questions
What is Enveric Biosciences focused on?
Enveric Biosciences is dedicated to developing novel neuroplastogen therapeutics.
What is EB-003?
EB-003 is the lead candidate in Enveric's EVM 301 series for neuropsychiatric disorders.
Who is Dr. Joseph Tucker?
Dr. Joseph Tucker is the CEO of Enveric Biosciences.
What advice does Dr. Tucker give to investors?
He offers insights on continuing investments in drug discovery in the psych space.